Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 21%
Hold 29%
Sell 7%
Strong Sell 0%

Bulls say

Tempus AI is well-positioned for long-term growth and success in the technology and healthcare industries with its innovative technology, recent acquisitions, strong market presence, and potential revenue growth from its personalized cancer vaccine program. Their use of AI and real-world data sets them apart from competitors, and their anticipated revenue growth shows potential for financial success. However, their success is heavily reliant on favorable reimbursement rates and maintaining market share.

Bears say

Tempus AI is facing multiple headwinds in the coming years, including delays in regulatory approval for their platform, intense competition in the healthcare and AI sectors, and a high valuation for their stock. Additionally, their partnership with Personalis may not yield expected results as it remains uncertain how their platform will integrate with Personalis' technology. The company also has a high cash burn rate, and it is unclear if they will be able to reach profitability in the near future. All these factors contribute to our negative outlook on the stock, as we believe it is overvalued and facing significant risks in the foreseeable future.

TEM has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 21% recommend Buy, 29% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 14 analysts, TEM has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.